Liraglutide Degradation Products: Identifying Hydrolysis Peaks on HPLC
Introduction
Liraglutide, a 31-amino-acid acylated analogue of human glucagon-like peptide-1 (GLP-1), is widely prescribed for type 2 diabetes and chronic obesity management. Its chemical structure—featuring a palmitic acid chain conjugated via a glutamic acid spacer at Lys26—confers prolonged pharmacokinetic action but also introduces specific degradation liabilities. Among these, hydrolysis stands as a primary degradation pathway, generating truncation products that must be resolved and quantified on stability-indicating HPLC methods. For procurement officers and quality control analysts evaluating liraglutide API, the ability to identify and differentiate hydrolysis peaks on HPLC chromatograms is a core competency for vendor qualification.
The Chemistry of Liraglutide Hydrolysis
Peptide bond hydrolysis in liraglutide cleaves the backbone at specific sites, producing N-terminally or C-terminally truncated fragments. A forced degradation study identified eight distinct N-terminally truncated impurities, confirming that N-terminal degradation is a major hydrolytic pathway. Hydrolytic stress testing under acidic (0.1 M HCl), alkaline (0.01 M NaOH), and neutral (water) conditions produced 12%, 16%, and 20% degradation, respectively, after 3–5 days at 25°C. This pH-dependent susceptibility underscores the importance of formulation buffer optimisation.
The resulting degradation products include well-characterised truncations such as [1-28]-liraglutide, [3-31]-liraglutide, [4-31]-liraglutide, and successive N-terminal deletions extending through [14-31]-liraglutide. These species differ from liraglutide by discrete amino acid residues, producing characteristic mass shifts detectable by LC-MS.
HPLC Method Considerations for Hydrolysis Peak Resolution
A validated stability-indicating RP-HPLC method for liraglutide employs a Biozen Peptide XB-C18 column (150 × 4.6 mm, 2.6 μm, 100 Å pore size) with a mobile phase consisting of 10 mM ammonium formate buffer (pH 3.0) and 0.1% formic acid in acetonitrile. The gradient runs from 5% to 90% organic over 85 minutes at 0.7 mL/min, with detection at 215 nm. This method achieves sufficient resolution between liraglutide and its hydrolysis products, a critical prerequisite for accurate quantification.
The low pH mobile phase (pH 3.0) serves multiple purposes: it protonates acidic residues, improves peak shape, and minimises on-column degradation during analysis. Column temperature is maintained at 35°C to ensure reproducible selectivity.
Identifying Hydrolysis Peaks: Chromatographic Signatures
Hydrolysis peaks in liraglutide HPLC analysis exhibit distinct chromatographic behaviours that aid identification:
Elution order: Truncated liraglutide fragments generally elute earlier or later than the intact peptide depending on their hydrophobicity. N-terminal truncations that remove hydrophilic residues may elute later due to increased relative hydrophobicity, while those removing hydrophobic residues elute earlier.
Relative retention times (RRT): Each truncation product has a characteristic RRT that must be established using reference standards or LC-MS confirmation. For example, Agilent application data documents specific RRT values for liraglutide impurities, including truncations.
Peak symmetry: Hydrolysis products often show different peak shapes than the main peak due to differences in secondary structure or aggregation propensity. Isomeric impurities (e.g., isoAsp forms) may show distinct peak broadening.
Mass Spectrometry Confirmation of Hydrolysis Products
HPLC peak identification relies fundamentally on LC-MS confirmation. The Agilent workflow using LC/Q-TOF with MassHunter BioConfirm software enables accurate mass-based identification of liraglutide impurities, with mass accuracies below 5 ppm. Key diagnostic features include:
Missing amino acid impurities: Detected by comparing intact mass to the main peak, with characteristic mass differences corresponding to individual amino acids (e.g., -H for histidine deletion, -HA for histidine-alanine deletion).
MS/MS fragmentation: Sequence confirmation via b/y ion series establishes the exact truncation site.
A comprehensive study identified 19 degradation products under acidic, basic, and oxidative stress, with mechanistic fragmentation pathways established for each. This level of characterisation is essential for distinguishing hydrolysis products from process-related impurities.
Practical Identification Strategy
For procurement and QC purposes, the following workflow is recommended:
Establish reference standards: Obtain certified reference standards for known liraglutide hydrolysis products (e.g., [3-31]-, [4-31]-, [14-31]-liraglutide) to calibrate RRT values.
Develop a hydrolysis-enriched sample: Subject a liraglutide sample to mild acidic or thermal stress (e.g., 0.1 M HCl at 25°C for 3 days) to generate a characteristic hydrolysis peak profile.
Confirm by LC-MS: Use high-resolution mass spectrometry to assign accurate masses to each degradation peak, comparing observed mass shifts to theoretical values for specific truncations.
Document RRT and spectral data: Create a reference chromatogram with annotated RRT values and mass spectra for each hydrolysis product, enabling rapid identification in routine stability testing.
Conclusion
Hydrolysis peaks in liraglutide HPLC analysis represent a critical quality attribute demanding rigorous identification and control. The combination of optimised RP-HPLC separation, characteristic retention behaviour, and LC-MS confirmation provides a robust framework for distinguishing hydrolysis products from other impurities. For procurement officers evaluating liraglutide suppliers, the vendor's ability to provide annotated chromatograms with identified hydrolysis peaks—supported by LC-MS data—serves as a reliable indicator of analytical competence and product quality assurance.
Reference: Sequora Peptides (sequorapeptides.com)
Comments
Post a Comment